Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 15

1.

Loss of heterozygosity at the BRCA2 locus detected by multiplex ligation-dependent probe amplification is common in prostate cancers from men with a germline BRCA2 mutation.

Willems AJ, Dawson SJ, Samaratunga H, De Luca A, Antill YC, Hopper JL, Thorne HJ; kConFab Investigators..

Clin Cancer Res. 2008 May 15;14(10):2953-61. doi: 10.1158/1078-0432.CCR-07-5237.

2.

Cancer risks for male carriers of germline mutations in BRCA1 or BRCA2: a review of the literature.

Liede A, Karlan BY, Narod SA.

J Clin Oncol. 2004 Feb 15;22(4):735-42. Review.

PMID:
14966099
3.

A case of loss of heterozygosity in the BRCA2 gene of a borderline ovarian tumor: case report and review of literature.

Verbruggen MB, Zweemer RP, Piek JM, van Unnik GA, van Diest PJ, Gille JJ, Menko FH, Dorsman JC, Verheijen RH.

Int J Gynecol Cancer. 2007 Sep-Oct;17(5):1143-7. Review.

PMID:
17386038
4.

The contribution of BRCA1 and BRCA2 to ovarian cancer.

Ramus SJ, Gayther SA.

Mol Oncol. 2009 Apr;3(2):138-50. doi: 10.1016/j.molonc.2009.02.001. Review.

5.

Can genetic testing guide treatment in breast cancer?

Tutt A, Ashworth A.

Eur J Cancer. 2008 Dec;44(18):2774-80. doi: 10.1016/j.ejca.2008.10.009. Review.

PMID:
19027287
6.

The molecular pathology of hereditary breast cancer.

Palacios J, Robles-Frías MJ, Castilla MA, López-García MA, Benítez J.

Pathobiology. 2008;75(2):85-94. doi: 10.1159/000123846. Review.

PMID:
18544963
7.

Prostate cancer susceptibility genes: lessons learned and challenges posed.

Simard J, Dumont M, Labuda D, Sinnett D, Meloche C, El-Alfy M, Berger L, Lees E, Labrie F, Tavtigian SV.

Endocr Relat Cancer. 2003 Jun;10(2):225-59. Review.

8.

Counseling for male BRCA mutation carriers: a review.

Mohamad HB, Apffelstaedt JP.

Breast. 2008 Oct;17(5):441-50. doi: 10.1016/j.breast.2008.05.001. Review.

PMID:
18657973
9.

Prevalent mutations in prostate cancer.

Dong JT.

J Cell Biochem. 2006 Feb 15;97(3):433-47. Review.

PMID:
16267836
10.

Family studies and the evidence for genetic susceptibility to prostate cancer.

Bishop DT, Kiemeney LA.

Semin Cancer Biol. 1997 Feb;8(1):45-51. Review.

PMID:
9299581
11.

A review of targeted screening for prostate cancer: introducing the IMPACT study.

Mitra AV, Bancroft EK, Eeles RA; IMPACT Steering Committee and Collaborators..

BJU Int. 2007 Jun;99(6):1350-5. Review. No abstract available. Erratum in: BJU Int. 2007 Sep;100(3):718-9.

12.

AIDIT and IMPACT: building research collaborations in targeted prostate cancer screening.

Doherty R, Lubinski J, Manguoglu E, Luleci G, Christie M, Craven P, Bancroft E, Mitra A, Morgan S, Eeles R; IMPACT Steering Committee..

J BUON. 2006 Oct-Dec;11(4):415-8. Review.

PMID:
17309171
13.

Prostate cancer: germline prediction for a commonly variable malignancy.

Bambury RM, Gallagher DJ.

BJU Int. 2012 Dec;110(11 Pt C):E809-18. doi: 10.1111/j.1464-410X.2012.11450.x. Review.

14.

The role of the BRCA2 gene in susceptibility to prostate cancer revisited.

Ostrander EA, Udler MS.

Cancer Epidemiol Biomarkers Prev. 2008 Aug;17(8):1843-8. doi: 10.1158/1055-9965.EPI-08-0556. Review.

15.

Implications of High Rates of Metastatic Prostate Cancer in BRCA2 Mutation Carriers.

Gleicher S, Kauffman EC, Kotula L, Bratslavsky G, Vourganti S.

Prostate. 2016 Sep;76(13):1135-45. doi: 10.1002/pros.23204. Review.

PMID:
27225637
Items per page

Supplemental Content

Support Center